# **Special Issue**

## Advances in Peptide Receptor Radionuclide Therapy

## Message from the Guest Editor

In recent years, peptide receptor radionuclide therapy (PRRT) has gained increasing interest since the NETTER-1 Phase III trial showed that patients with midgut neuroendocrine tumors (NETs) achieved better outcomes with PRRT compared to a group treated with a somatostatin receptor analog; longer progression-free survival (p < 0.001), better overall response and, presumably, better overall survival (median not reached; p = 0.004). There are also currently several approaches to increasing the effectiveness of PRRT, for example, alpha-targeted treatment instead of PRRT with beta particles, antagonists SSTR-targeting instead of agonists, intra-arterial PRRT instead of intravenous application and PRRT combined with other therapies. Furthermore, the targeting of somatostatin receptors can also be applied for some disorders and tumors other than NETs, such as thyroid cancer, refractory meningioma and sarcoidosis. In this special issue of Pharmaceuticals, we would like to present articles focusing on current promising modifications of PRRT for the therapy of NETs, recent reports from prospective trials, novel combination therapies and examples of PRRT applications for non-NET diseases.

### **Guest Editor**

Dr. Anna Yordanova

Department of Radiology, Marienhospital Bonn, 53127 Bonn, Germany

## Deadline for manuscript submissions

closed (25 March 2022)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/74940

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

#### **Author Benefits**

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

